Insulet Co. (NASDAQ:PODD) Shares Acquired by Bellevue Group AG

Bellevue Group AG lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 1.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 293,828 shares of the medical instruments supplier’s stock after acquiring an additional 3,928 shares during the period. Bellevue Group AG’s holdings in Insulet were worth $50,362,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Capital Research Global Investors raised its stake in Insulet by 19.7% during the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after purchasing an additional 1,556,455 shares during the period. Baillie Gifford & Co. purchased a new stake in shares of Insulet during the 4th quarter valued at approximately $263,144,000. Norges Bank acquired a new position in Insulet in the fourth quarter valued at approximately $227,655,000. Goldman Sachs Group Inc. grew its position in Insulet by 56.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock worth $190,623,000 after acquiring an additional 316,649 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in Insulet by 206.9% during the first quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock worth $73,632,000 after acquiring an additional 289,591 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of several recent analyst reports. Raymond James decreased their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research note on Friday, May 10th. Barclays decreased their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. Jefferies Financial Group lifted their price target on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Redburn Atlantic assumed coverage on shares of Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $234.00 target price on shares of Insulet in a report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $239.18.

Insider Buying and Selling

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the sale, the director now directly owns 42,586 shares in the company, valued at $7,703,807.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now owns 12,875 shares in the company, valued at approximately $2,574,485. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the transaction, the director now owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,931 shares of company stock worth $2,636,286. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Up 1.3 %

PODD stock traded up $2.42 during mid-day trading on Friday, reaching $193.30. The company had a trading volume of 1,848,011 shares, compared to its average volume of 522,031. The firm has a fifty day simple moving average of $193.24 and a 200 day simple moving average of $184.45. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. The company has a market capitalization of $13.54 billion, a price-to-earnings ratio of 58.58, a price-to-earnings-growth ratio of 3.48 and a beta of 1.16. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $283.00.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm had revenue of $441.70 million for the quarter, compared to analysts’ expectations of $424.05 million. During the same quarter last year, the company earned $0.23 earnings per share. The firm’s revenue was up 23.3% compared to the same quarter last year. Analysts forecast that Insulet Co. will post 3.11 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.